Genix Pharmaceuticals Corporation (TSE:GENX) has released an update.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Genix Pharmaceuticals Corporation has received TSX Venture Exchange approval for amendments to their warrants, including a reduction in exercise price from $0.30 to $0.15 per share and an extension of the expiry dates to July and August 2025. The company has corrected the total number of warrants from previous releases and issued an apology for any confusion caused by past clerical errors. Genix is a company specializing in novel and generic ophthalmic drugs, focusing on the development and sale of proprietary healthcare products.
For further insights into TSE:GENX stock, check out TipRanks’ Stock Analysis page.